These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20494961)

  • 1. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).
    Ohno S; Rai Y; Iwata H; Yamamoto N; Yoshida M; Iwase H; Masuda N; Nakamura S; Taniguchi H; Kamigaki S; Noguchi S
    Ann Oncol; 2010 Dec; 21(12):2342-2347. PubMed ID: 20494961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
    Pritchard KI; Rolski J; Papai Z; Mauriac L; Cardoso F; Chang J; Panasci L; Ianuli C; Kahan Z; Fukase K; Lindemann JP; Macpherson MP; Neven P
    Breast Cancer Res Treat; 2010 Sep; 123(2):453-61. PubMed ID: 20632084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
    Xu B; Jiang Z; Shao Z; Wang J; Feng J; Song S; Chen Z; Gu K; Yu S; Zhang Y; Wang C; Zhang F; Yang J
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):223-30. PubMed ID: 20938664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
    Howell A; Robertson JF; Abram P; Lichinitser MR; Elledge R; Bajetta E; Watanabe T; Morris C; Webster A; Dimery I; Osborne CK
    J Clin Oncol; 2004 May; 22(9):1605-13. PubMed ID: 15117982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
    Di Leo A; Jerusalem G; Petruzelka L; Torres R; Bondarenko IN; Khasanov R; Verhoeven D; Pedrini JL; Smirnova I; Lichinitser MR; Pendergrass K; Garnett S; Lindemann JP; Sapunar F; Martin M
    J Clin Oncol; 2010 Oct; 28(30):4594-600. PubMed ID: 20855825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
    Osborne CK; Pippen J; Jones SE; Parker LM; Ellis M; Come S; Gertler SZ; May JT; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
    J Clin Oncol; 2002 Aug; 20(16):3386-95. PubMed ID: 12177098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
    Blancas I; Fontanillas M; Conde V; Lao J; Martínez E; Sotelo MJ; Jaen A; Bayo JL; Carabantes F; Illarramendi JJ; Gordon MM; Cruz J; García-Palomo A; Mendiola C; Pérez-Ruiz E; Bofill JS; Baena-Cañada JM; Jáñez NM; Esquerdo G; Ruiz-Borrego M
    Clin Transl Oncol; 2018 Jul; 20(7):862-869. PubMed ID: 29178019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
    Robertson JF; Erikstein B; Osborne KC; Pippen J; Come SE; Parker LM; Gertler S; Harrison MP; Clarke DA
    Clin Pharmacokinet; 2004; 43(8):529-38. PubMed ID: 15170367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant (Faslodex) -- how to make a good drug better.
    Robertson JF
    Oncologist; 2007 Jul; 12(7):774-84. PubMed ID: 17673609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
    Chia S; Gradishar W; Mauriac L; Bines J; Amant F; Federico M; Fein L; Romieu G; Buzdar A; Robertson JF; Brufsky A; Possinger K; Rennie P; Sapunar F; Lowe E; Piccart M
    J Clin Oncol; 2008 Apr; 26(10):1664-70. PubMed ID: 18316794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).
    Kimizuka K; Inoue K; E Nagai S; Saito T; Nakano S; Futsuhara K; Yamada H; Kaneko S; Sakurai T; Hata S; Kurosumi M
    J Nippon Med Sch; 2019; 86(3):165-171. PubMed ID: 31292328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
    Robertson JF; Llombart-Cussac A; Rolski J; Feltl D; Dewar J; Macpherson E; Lindemann J; Ellis MJ
    J Clin Oncol; 2009 Sep; 27(27):4530-5. PubMed ID: 19704066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
    Howell A; Robertson JF; Quaresma Albano J; Aschermannova A; Mauriac L; Kleeberg UR; Vergote I; Erikstein B; Webster A; Morris C
    J Clin Oncol; 2002 Aug; 20(16):3396-403. PubMed ID: 12177099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
    Robertson JF; Lindemann JP; Llombart-Cussac A; Rolski J; Feltl D; Dewar J; Emerson L; Dean A; Ellis MJ
    Breast Cancer Res Treat; 2012 Nov; 136(2):503-11. PubMed ID: 23065000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
    Martínez Marín V; Muñoz Martín AJ; Viñuela Benéitez MC; García Alfonso P; Alonso Muñoz A; Pérez Manga G
    Med Clin (Barc); 2009 Sep; 133(10):371-4. PubMed ID: 19339025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China.
    Zhang Q; Shao Z; Shen K; Li L; Feng J; Tong Z; Gu K; Wang X; Xu B; Sun G; Chen H; Rukazenkov Y; Jiang Z
    Oncotarget; 2016 Aug; 7(35):57301-57309. PubMed ID: 27359058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
    Gong DD; Man CF; Xu J; Fan Y
    Asian Pac J Cancer Prev; 2014; 15(5):2095-100. PubMed ID: 24716940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
    Croxtall JD; McKeage K
    Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
    Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
    Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.